Cargando…

Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study

Patients with underlying medical conditions are at high risk of developing serious symptoms of the coronavirus disease 2019 than healthy individuals; therefore, it is necessary to evaluate the immune response to vaccination among them to formulate precision and personalized vaccination strategies. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiaqi, Nakagawa, Takeshi, Kojima, Masayo, Nishikimi, Akihiko, Tokuda, Haruhiko, Nishimura, Kunihiro, Umezawa, Jun, Tanaka, Shiori, Inoue, Manami, Ohmagari, Norio, Yamaguchi, Koushi, Takeda, Kazuyoshi, Yamamoto, Shohei, Konishi, Maki, Miyo, Kengo, Mizoue, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079051/
https://www.ncbi.nlm.nih.gov/pubmed/37023035
http://dx.doi.org/10.1371/journal.pone.0283658
_version_ 1785020644573839360
author Li, Jiaqi
Nakagawa, Takeshi
Kojima, Masayo
Nishikimi, Akihiko
Tokuda, Haruhiko
Nishimura, Kunihiro
Umezawa, Jun
Tanaka, Shiori
Inoue, Manami
Ohmagari, Norio
Yamaguchi, Koushi
Takeda, Kazuyoshi
Yamamoto, Shohei
Konishi, Maki
Miyo, Kengo
Mizoue, Tetsuya
author_facet Li, Jiaqi
Nakagawa, Takeshi
Kojima, Masayo
Nishikimi, Akihiko
Tokuda, Haruhiko
Nishimura, Kunihiro
Umezawa, Jun
Tanaka, Shiori
Inoue, Manami
Ohmagari, Norio
Yamaguchi, Koushi
Takeda, Kazuyoshi
Yamamoto, Shohei
Konishi, Maki
Miyo, Kengo
Mizoue, Tetsuya
author_sort Li, Jiaqi
collection PubMed
description Patients with underlying medical conditions are at high risk of developing serious symptoms of the coronavirus disease 2019 than healthy individuals; therefore, it is necessary to evaluate the immune response to vaccination among them to formulate precision and personalized vaccination strategies. However, inconsistent evidence exists regarding whether patients with underlying medical conditions have lower anti-SARS-CoV-2 spike IgG antibody titers. We performed a cross-sectional study enrolling 2762 healthcare workers who received second doses of BNT162b2 vaccination from three medical and research institutes between June and July, 2021. Medical conditions were surveyed by a questionnaire, and spike IgG antibody titers were measured with chemiluminescent enzyme immunoassay using serum collected on the median of 62 days after the second vaccination. Multilevel linear regression model was used to estimate geometric mean and ratio of mean (95% confidence interval, CI) for the presence and absence of medical conditions and treatments. Among all participants (median age, 40 years [interquartile range, 30–50]; male proportion, 29.4%), the prevalence of hypertension, diabetes, chronic lung disease, cardiovascular disease, and cancer was 7.5%, 2.3%, 3.8%, 1.8%, and 1.3%, respectively. Patients with treated hypertension had lower antibody titers than those without hypertension; the multivariable-adjusted ratio of mean (95% CI) was 0.86 (0.76–0.98). Patients with untreated and treated diabetes had lower antibody titers than those without diabetes; the multivariable-adjusted ratio of mean (95% CI) was 0.63 (0.42–0.95) and 0.77 (0.63–0.95), respectively. No substantial difference was observed between the presence or absence of chronic lung disease, cardiovascular disease, or cancer. Patients with untreated hypertension and patients with untreated and treated diabetes had lower spike IgG antibody titers than participants without those medical conditions, suggesting that continuous monitoring of antibody titers and further booster shots could be necessary to maintain adaptive immunity in patients with hypertension or diabetes.
format Online
Article
Text
id pubmed-10079051
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100790512023-04-07 Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study Li, Jiaqi Nakagawa, Takeshi Kojima, Masayo Nishikimi, Akihiko Tokuda, Haruhiko Nishimura, Kunihiro Umezawa, Jun Tanaka, Shiori Inoue, Manami Ohmagari, Norio Yamaguchi, Koushi Takeda, Kazuyoshi Yamamoto, Shohei Konishi, Maki Miyo, Kengo Mizoue, Tetsuya PLoS One Research Article Patients with underlying medical conditions are at high risk of developing serious symptoms of the coronavirus disease 2019 than healthy individuals; therefore, it is necessary to evaluate the immune response to vaccination among them to formulate precision and personalized vaccination strategies. However, inconsistent evidence exists regarding whether patients with underlying medical conditions have lower anti-SARS-CoV-2 spike IgG antibody titers. We performed a cross-sectional study enrolling 2762 healthcare workers who received second doses of BNT162b2 vaccination from three medical and research institutes between June and July, 2021. Medical conditions were surveyed by a questionnaire, and spike IgG antibody titers were measured with chemiluminescent enzyme immunoassay using serum collected on the median of 62 days after the second vaccination. Multilevel linear regression model was used to estimate geometric mean and ratio of mean (95% confidence interval, CI) for the presence and absence of medical conditions and treatments. Among all participants (median age, 40 years [interquartile range, 30–50]; male proportion, 29.4%), the prevalence of hypertension, diabetes, chronic lung disease, cardiovascular disease, and cancer was 7.5%, 2.3%, 3.8%, 1.8%, and 1.3%, respectively. Patients with treated hypertension had lower antibody titers than those without hypertension; the multivariable-adjusted ratio of mean (95% CI) was 0.86 (0.76–0.98). Patients with untreated and treated diabetes had lower antibody titers than those without diabetes; the multivariable-adjusted ratio of mean (95% CI) was 0.63 (0.42–0.95) and 0.77 (0.63–0.95), respectively. No substantial difference was observed between the presence or absence of chronic lung disease, cardiovascular disease, or cancer. Patients with untreated hypertension and patients with untreated and treated diabetes had lower spike IgG antibody titers than participants without those medical conditions, suggesting that continuous monitoring of antibody titers and further booster shots could be necessary to maintain adaptive immunity in patients with hypertension or diabetes. Public Library of Science 2023-04-06 /pmc/articles/PMC10079051/ /pubmed/37023035 http://dx.doi.org/10.1371/journal.pone.0283658 Text en © 2023 Li et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Li, Jiaqi
Nakagawa, Takeshi
Kojima, Masayo
Nishikimi, Akihiko
Tokuda, Haruhiko
Nishimura, Kunihiro
Umezawa, Jun
Tanaka, Shiori
Inoue, Manami
Ohmagari, Norio
Yamaguchi, Koushi
Takeda, Kazuyoshi
Yamamoto, Shohei
Konishi, Maki
Miyo, Kengo
Mizoue, Tetsuya
Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title_full Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title_fullStr Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title_full_unstemmed Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title_short Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
title_sort underlying medical conditions and anti-sars-cov-2 spike igg antibody titers after two doses of bnt162b2 vaccination: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079051/
https://www.ncbi.nlm.nih.gov/pubmed/37023035
http://dx.doi.org/10.1371/journal.pone.0283658
work_keys_str_mv AT lijiaqi underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT nakagawatakeshi underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT kojimamasayo underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT nishikimiakihiko underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT tokudaharuhiko underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT nishimurakunihiro underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT umezawajun underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT tanakashiori underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT inouemanami underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT ohmagarinorio underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT yamaguchikoushi underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT takedakazuyoshi underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT yamamotoshohei underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT konishimaki underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT miyokengo underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy
AT mizouetetsuya underlyingmedicalconditionsandantisarscov2spikeiggantibodytitersaftertwodosesofbnt162b2vaccinationacrosssectionalstudy